|
1
|
Amin MB, Edge S, Greene F, Byrd DR,
Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR,
Sullivan DC, et al: AJCC Cancer Staging Manual. 8th edition.
Springer; New York, NY: 2017, View Article : Google Scholar
|
|
2
|
Nemoto T, Vana J, Bedwani RN, Baker HW,
McGregor FH and Murphy GP: Management and survival of female breast
cancer: Results of a national survey by the American College of
Surgeons. Cancer. 45:2917–2924. 1980. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Walker MJ, Osborne MD, Young DC,
Schneebaum S, La Valle GJ and Farrar WB: The natural history of
breast cancer with more than 10 positive nodes. Am J Surg.
169:575–579. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Buzdar AU, Kau SW, Hortobagyi GN, Ames FC,
Holmes FA, Fraschini G, Hug V, Theriault RL, McNeese MD and
Singletary SE: Clinical course of patients with breast cancer with
ten or more positive nodes who were treated with
doxorubicin-containing adjuvant therapy. Cancer. 69:448–452. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Schmoor C, Sauerbrei W, Bastert G, Bojar H
and Schumacher M: German Breast Cancer Study Group: Long-term
prognosis of breast cancer patients with 10 or more positive lymph
nodes treated with CMF. Eur J Cancer. 37:1123–1131. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Basaran G, Devrim C, Caglar HB, Gulluoglu
B, Kaya H, Seber S, Korkmaz T, Telli F, Kocak M, Dane F, et al:
Clinical outcome of breast cancer patients with N3a (≥10 positive
lymph nodes) disease: Has it changed over years? Med Oncol.
28:726–732. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Perou CM, Sørlie T, Eisen MB, van de Rijn
M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA,
et al: Molecular portraits of human breast tumours. Nature.
406:747–752. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sørlie T, Perou CM, Tibshirani R, Aas T,
Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey
SS, et al: Gene expression patterns of breast carcinomas
distinguish tumor subclasses with clinical implications. Proc Natl
Acad Sci USA. 98:10869–10874. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sotiriou C, Neo SY, McShane LM, Korn EL,
Long PM, Jazaeri A, Martiat P, Fox SB, Harris AL and Liu ET: Breast
cancer classification and prognosis based on gene expression
profiles from a population-based study. Proc Natl Acad Sci USA.
100:10393–10398. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Abd El-Rehim DM, Ball G, Pinder SE, Rakha
E, Paish C, Robertson JF, Macmillan D, Blamey RW and Ellis IO:
High-throughput protein expression analysis using tissue microarray
technology of a large well-characterised series identifies
biologically distinct classes of breast cancer confirming recent
cDNA expression analyses. Int J Cancer. 116:340–350. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yersal O and Barutca S: Biological
subtypes of breast cancer: Prognostic and therapeutic implications.
World J Clin Oncol. 5:412–424. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cianfrocca M and Goldstein LJ: Prognostic
and predictive factors in early-stage breast cancer. Oncologist.
9:606–616. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kennecke H, Yerushalmi R, Woods R, Cheang
MC, Voduc D, Speers CH, Nielsen TO and Gelmon K: Metastatic
behavior of breast cancer subtypes. J Clin Oncol. 28:3271–3277.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yang ZJ, Yu Y, Hou XW, Chi JR, Ge J, Wang
X and Cao XC: The prognostic value of node status in different
breast cancer subtypes. Oncotarget. 8:4563–4571. 2017.PubMed/NCBI
|
|
15
|
Kim YY, Park HK, Lee KH, Kim KI and Chun
YS: Prognostically distinctive subgroup in pathologic N3 breast
cancer. J Breast Cancer. 19:163–168. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liu N, Yang Z, Liu X and Niu Y: Lymph node
status in different molecular subtype of breast cancer: Triple
negative tumours are more likely lymph node negative. Oncotarget.
8:55534–55543. 2017.PubMed/NCBI
|
|
17
|
Bria E, Nistico C, Cuppone F, Carlini P,
Ciccarese M, Milella M, Natoli G, Terzoli E, Cognetti F and
Giannarelli D: Benefit of taxanes as adjuvant chemotherapy for
early breast cancer: Pooled analysis of 15,500 patients. Cancer.
106:2337–2344. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
De Laurentiis M, Cancello G, D'Agostino D,
Giuliano M, Giordano A, Montagna E, Lauria R, Forestieri V,
Esposito A, Silvestro L, et al: Taxane-based combinations as
adjuvant chemotherapy of early breast cancer: A meta-analysis of
randomized trials. J Clin Oncol. 26:44–53. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ferguson T, Wilcken N, Vagg R, Ghersi D
and Nowak AK: Taxanes for adjuvant treatment of early breast
cancer. Cochrane Database Syst Rev. 4:CD0044212007.
|
|
20
|
Perez EA, Romond EH, Suman VJ, Jeong JH,
Sledge G, Geyer CE Jr, Martino S, Rastogi P, Gralow J, Swain SM, et
al: Trastuzumab plus adjuvant chemotherapy for human epidermal
growth factor receptor 2-positive breast cancer: Planned joint
analysis of overall survival from NSABP B-31 and NCCTG N9831. J
Clin Oncol. 32:3744–3752. 2014. View Article : Google Scholar : PubMed/NCBI
|
